Northern Trust Corp Rigel Pharmaceuticals Inc Transaction History

Northern Trust Corp

$600 Billion
Q3 2024

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 14, 2024	SELL	$1.12 - $1.57 $105,118 - $147,353	-93,856 Reduced 6.09%	1,447,748 $2.14 Million
Q4 2023 Feb 13, 2024	BUY	$0.72 - $1.56 $17,261 - $37,399	23,974 Added 1.58%	1,541,604 $2.24 Million
Q3 2023 Nov 13, 2023	BUY	$1.07 - $1.39 $4,533 - $5,889	4,237 Added 0.28%	1,517,630 $1.64 Million
Q2 2023 Aug 11, 2023	SELL	$1.12 - $1.82 $6,618 - $10,754	-5,909 Reduced 0.39%	1,513,393 $1.95 Million
Q1 2023 May 15, 2023	BUY	$1.25 - $2.0 $12,620 - $20,192	10,096 Added 0.67%	1,519,302 $2.01 Million
Q4 2022 Feb 13, 2023	SELL	$0.67 - $11.9 $71,336 - $1.27 Million	-106,472 Reduced 6.59%	1,509,206 $2.26 Million
Q3 2022 Nov 14, 2022	SELL	$1.1 - $12.2 $32,506 - $360,522	-29,551 Reduced 1.8%	1,615,678 $1.91 Million
Q2 2022 Aug 12, 2022	SELL	$0.67 - $3.19 $36,847 - $175,437	-54,996 Reduced 3.23%	1,645,229 $1.86 Million
Q1 2022 May 13, 2022	SELL	$2.22 - $3.45 $175,890 - $273,343	-79,230 Reduced 4.45%	1,700,225 $5.08 Million
Q4 2021 Feb 08, 2022	BUY	$2.36 - $3.57 $52,835 - $79,925	22,388 Added 1.27%	1,779,455 $4.72 Million
Q3 2021 Nov 15, 2021	SELL	$3.5 - $4.5 $147,700 - $189,900	-42,200 Reduced 2.35%	1,757,067 $6.38 Million
Q2 2021 Aug 13, 2021	SELL	$3.09 - $4.54 $220,483 - $323,947	-71,354 Reduced 3.81%	1,799,267 $7.81 Million
Q1 2021 May 12, 2021	SELL	$3.35 - $4.93 $331,147 - $487,330	-98,850 Reduced 5.02%	1,870,621 $6.4 Million
Q4 2020 Feb 11, 2021	SELL	$2.35 - $3.74 $50,132 - $79,785	-21,333 Reduced 1.07%	1,969,471 $6.89 Million
Q3 2020 Nov 16, 2020	SELL	$1.78 - $4.13 $215,908 - $500,956	-121,297 Reduced 5.74%	1,990,804 $4.78 Million
Q2 2020 Aug 14, 2020	SELL	$1.41 - $2.05 $13,175 - $19,155	-9,344 Reduced 0.44%	2,112,101 $3.87 Million
Q1 2020 May 14, 2020	SELL	$1.27 - $3.0 $25,312 - $59,793	-19,931 Reduced 0.93%	2,121,445 $3.31 Million
Q4 2019 Feb 14, 2020	BUY	$1.6 - $2.43 $86,112 - $130,782	53,820 Added 2.58%	2,141,376 $4.58 Million
Q3 2019 Nov 13, 2019	BUY	$1.63 - $2.62 $89,861 - $144,440	55,130 Added 2.71%	2,087,556 $3.9 Million
Q2 2019 Aug 13, 2019	BUY	$2.02 - $2.61 $48,340 - $62,459	23,931 Added 1.19%	2,032,426 $5.31 Million
Q1 2019 May 13, 2019	SELL	$2.0 - $2.65 $5,294 - $7,014	-2,647 Reduced 0.13%	2,008,495 $5.16 Million
Q4 2018 Feb 12, 2019	SELL	$2.08 - $3.36 $85,702 - $138,442	-41,203 Reduced 2.01%	2,011,142 $4.63 Million
Q3 2018 Nov 14, 2018	BUY	$2.6 - $3.59 $145,537 - $200,953	55,976 Added 2.8%	2,052,345 $6.59 Million
Q2 2018 Sep 18, 2018	SELL	$2.83 - $4.11 $29,304 - $42,559	-10,355 Reduced 0.52%	1,996,369 $5.65 Million
Q2 2018 Aug 14, 2018	BUY	$2.83 - $4.11 $651,695 - $946,454	230,281 Added 12.96%	2,006,724 $5.68 Million
Q1 2018 May 09, 2018	BUY	$3.54 - $4.54 $130,427 - $167,271	36,844 Added 2.12%	1,776,443 $6.29 Million
Q4 2017 Feb 14, 2018	BUY	$3.23 - $4.3 $807,697 - $1.08 Million	250,061 Added 16.79%	1,739,599 $6.75 Million
Q3 2017 Nov 13, 2017	BUY	$2.18 - $2.57 $3.25 Million - $3.83 Million	1,489,538	1,489,538 $3.78 Million

Others Institutions Holding RIGL

# of Institutions

Shares Held

334K

Call Options Held

Put Options Held

View Full List

About RIGEL PHARMACEUTICALS INC

Ticker RIGL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 172,836,000
Market Cap $2.96B
Description
Rigel Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs to treat hematologic disorders, cancer, and rare immune diseases. The company offers Tavalisse, an oral spleen tyrosine kinase inhibitor for the treatment of adult patients with chronic immune thrombocytopenia. It also develops Fostamatinib that is ...

More about RIGL

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.

Account